Publication date: 5 June 2018
Source:Cell Metabolism, Volume 27, Issue 6
Author(s): Yihai Cao
Drugs that target angiogenesis are commonly used for treating various cancers, but their clinical benefits are limited. In a recent Science Translational Medicine article, Incio et al. (2018) provide mechanistic insight on the role of obesity in the development of anti-VEGF drug resistance in human patients and murine models of breast cancer.
Teaser
Drugs that target angiogenesis are commonly used for treating various cancers, but their clinical benefits are limited. In a recent Science Translational Medicine article, Incio et al. (2018) provide mechanistic insight on the role of obesity in the development of anti-VEGF drug resistance in human patients and murine models of breast cancer.https://ift.tt/2HoPADP
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου